Articles related to LIVER CANCER
90Y Radioembolization in the Treatment of Neuroendocrine Neoplasms: Results of an International Multicenter Retrospective Study
In patients with NETs with distant metastasis, 90Y radioembolization (90Y RE) might be an important treatment option; however, data to support clinical benefits are scarce. The authors purposed to analyze the use of 90Y RE in NET patients with hepatic metastases in an international, multicenter retrospective analysis. In reviewing response data, they conclude that 90Y RE could be an important alternative to peptide receptor radionuclide therapy as second-line treatment in patients with progressive liver-dominant disease pretreated with somatostatin analogs.
Oncology, Medical May 31st 2022
10-year review of health insurance data set reveals possible protective effect of H1 antihistamines in preventing hepatic cancer
Antihistamine use in patients with HBV, HCV, or dual virus infections was associated with approximately two-fold lower risk of HCC when compared with patients who did not use antihistamines, in a dose-dependent manner.
Oncology, Medical May 10th 2022
Breaking the Child-Pugh Dogma in Hepatocellular Carcinoma (HCC)
Recently, the ALBI (albumin-bilirubin) score has been developed as an HCC-specific refinement of the Child-Pugh (C-P) score. In this commentary, the authors summarize the limitations of the C-P score, which include subjectivity and inconsistency of versions, as well as lack of sensitivity in patients with mild liver dysfunction. In comparison, the ALBI score “is entirely objective, obviating any need for subjective assessment of clinical signs, that it is derived from an entirely HCC population and is a continuous score that readily lends itself for assessment of changes in liver reserve over time.”
Oncology, Medical April 5th 2022
Treatment Approaches for Advanced Hepatocellular Carcinoma: Insight From the 2022 Gastrointestinal Cancers Symposium
A potentially practice-changing clinical trial for first line therapy is the first to show that the combination of two immunotherapy medications is an effective treatment for hepatocellular carcinoma (HCC). The HIMALAYA study evaluated combination immunotherapy (IO-IO), durvalumab with tremelimumab, as frontline therapy in patients with unresectable HCC. Overall survival was significantly improved with the IO-IO combination compared with sorafenib monotherapy (16.4 vs 13.8 months; hazard ratio [HR], 0.78; 96% CI, 0.65-0.92; P =.0035). Early results of the phase three LAUNCH trial are also promising. This trial compared the combination of lenvatinib with transarterial chemoembolization (TACE) to lenvatinib alone in an Asian population with advanced HCC. The lenvatinib-TACE group achieved a higher median overall survival (17.8 vs. 11.5 months and median progression-free survival (10.6 vs. 6.4 months). Muhammad Shaalan Beg, MD, director for GI Medical Oncology at UT Southwestern Medical Center in Dallas summarizes these and other takeaways from emerging research on advanced HCC presented at the recent ASCO GI Symposium.
Gastroenterology March 1st 2022
Drug Combination Gets Advanced Liver Cancer Patients to Surgery
Research from Johns Hopkins Kimmel Cancer Center showed that combination therapy of cabozantinib and nivolumab could make curative surgery possible for some liver cancer patients who would normally not be considered for such a procedure. Among 15 people with hepatocellular carcinoma (HCC) in the study who could not be treated previously with surgery, the drugs allowed 12 patients to undergo successful surgical removal of their cancer. Five of these 12 patients had only 10% or less of their tumor remaining after the drug treatment.
Gastroenterology November 9th 2021
ASCO Hepatocellular Carcinoma Guideline Updates
Available from Guideline Central, the free, quick-reference print and digital pocket guide covers the most recent American Society of Clinical Oncology (ASCO) Hepatocellular Carcinoma Guidelines. Accessed by web and offline mobile devices, the pocket guide covers key points, treatment, first- and second-line therapies, a downloadable PDF, and links to other resources in advanced hepatocellular carcinoma.
Hepatology September 14th 2021